SanBio Company Limited
SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. The company's research pipeline products also comprise SB623 for chronic cerebral infarction and chronic traumatic cerebral infarction inj… Read more
SanBio Company Limited (SNBIF) - Total Assets
Latest total assets as of July 2025: $3.22 Billion USD
Based on the latest financial reports, SanBio Company Limited (SNBIF) holds total assets worth $3.22 Billion USD as of July 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
SanBio Company Limited - Total Assets Trend (2014–2025)
This chart illustrates how SanBio Company Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
SanBio Company Limited - Asset Composition Analysis
Current Asset Composition (January 2025)
SanBio Company Limited's total assets of $3.22 Billion consist of 96.8% current assets and 3.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 84.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how SanBio Company Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SanBio Company Limited's current assets represent 96.8% of total assets in 2025, an increase from 95.6% in 2014.
- Cash Position: Cash and equivalents constituted 84.7% of total assets in 2025, down from 92.4% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
SanBio Company Limited Competitors by Total Assets
Key competitors of SanBio Company Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx SE
OTCGREY:ARGNF
|
USA | $7.18 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Exicure Inc
NASDAQ:XCUR
|
USA | $15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
SanBio Company Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - SanBio Company Limited generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - SanBio Company Limited is currently not profitable relative to its asset base.
SanBio Company Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.30 | 5.30 | 4.48 |
| Quick Ratio | 6.30 | 5.30 | 4.31 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.62 Billion | $ 2.79 Billion | $ 9.11 Billion |
SanBio Company Limited - Advanced Valuation Insights
This section examines the relationship between SanBio Company Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 135.51 |
| Latest Market Cap to Assets Ratio | 0.10 |
| Asset Growth Rate (YoY) | -31.7% |
| Total Assets | $3.45 Billion |
| Market Capitalization | $354.45 Million USD |
Valuation Analysis
Below Book Valuation: The market values SanBio Company Limited's assets below their book value (0.10 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: SanBio Company Limited's assets decreased by 31.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for SanBio Company Limited (2014–2025)
The table below shows the annual total assets of SanBio Company Limited from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-01-31 | $3.45 Billion | -31.70% |
| 2024-01-31 | $5.05 Billion | -28.36% |
| 2023-01-31 | $7.05 Billion | +27.84% |
| 2022-01-31 | $5.51 Billion | -58.70% |
| 2021-01-31 | $13.34 Billion | -14.49% |
| 2020-01-31 | $15.61 Billion | +11.66% |
| 2019-01-31 | $13.98 Billion | +169.13% |
| 2018-01-31 | $5.19 Billion | -17.47% |
| 2017-01-31 | $6.29 Billion | -23.93% |
| 2016-01-31 | $8.27 Billion | +371.28% |
| 2015-01-31 | $1.75 Billion | +270.25% |
| 2014-01-31 | $474.00 Million | -- |